We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

253 hedge funds and large institutions have $462M invested in Iovance Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 81 increasing their positions, 79 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

67% more call options, than puts

Call options by funds: $7.47M | Put options by funds: $4.47M

22% more capital invested

Capital invested by funds: $379M → $462M (+$83M)

3% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 79

3% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 40

1% less funds holding

Funds holding: 255 → 253 (-2)

7.1% less ownership

Funds ownership: 65.97% → 58.87% (-7.1%)

Holders
253
Holders Change
-2
Holders Change %
-0.78%
% of All Funds
3.32%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
41
Increased
81
Reduced
79
Closed
40
Calls
$7.47M
Puts
$4.47M
Net Calls
+$3M
Net Calls Change
+$1.97M

Top Buyers

Rank Fund Capital Flow
1
PAI
Palo Alto Investors
California
+$9.89M
2
State Street
State Street
Massachusetts
+$8.07M
3
BlackRock
BlackRock
New York
+$6.42M
4
Bank of America
Bank of America
North Carolina
+$5.31M
5
ICM
Invenomic Capital Management
Massachusetts
+$5.31M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$11.6M
2
Renaissance Technologies
Renaissance Technologies
New York
-$8.41M
3
LFCM
Long Focus Capital Management
Puerto Rico
-$6.38M
4
SCM
Soleus Capital Management
Connecticut
-$5.4M
5
Two Sigma Investments
Two Sigma Investments
New York
-$4.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
Lazard Asset Management
276
Lazard Asset Management
New York
– -$13K -7,744 Closed
SC
277
SouthState Corp
Florida
– -$8.6K -5,000 Closed
QT
278
Quantbot Technologies
New York
– -$5.78K -3,362 Closed
AUB
279
Atlantic Union Bankshares
Virginia
– -$1.38K -800 Closed
GWM
280
Geneos Wealth Management
Colorado
– -$1.21K -705 Closed
TWC
281
TD Waterhouse Canada
Ontario, Canada
– -$1.03K -598 Closed
RI
282
Ridgewood Investments
New Jersey
– -$516 -300 Closed
PWA
283
Physician Wealth Advisors
Utah
– -$491 -285 Closed
SO
284
Sierra Ocean
California
– -$454 -264 Closed
CIBC Private Wealth Group
285
CIBC Private Wealth Group
Georgia
– -$284 -165 Closed
FFO
286
Fortitude Family Office
Arizona
– -$244 -142 Closed
KIM
287
Kestra Investment Management
Texas
– -$470 -141 Closed
PA
288
Parallel Advisors
California
– -$148 -86 Closed
AW
289
Avion Wealth
Texas
– +$633 +268 New
8 9 10 11
12

IOVA Hedge Fund Activity: Q3 2025 in Review

253 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2025, worth a combined $462M — up 22% from $379M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new IOVA positions and 40 closed out — a net gain of 1 holder — while 81 added to existing stakes and 79 trimmed.

The largest buyer was Palo Alto Investors, adding an estimated $9.89M. The largest seller was Millennium Management, cutting an estimated $11.6M.

  • 253 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2025, down from 255 in Q2 2025.
  • Funds reported $462M of Iovance Biotherapeutics stock for Q3 2025, up 22% quarter-over-quarter.
  • 41 funds opened new Iovance Biotherapeutics positions in Q3 2025 and 40 closed out, a net change of +1 holder.
  • The largest Iovance Biotherapeutics buyer in Q3 2025 was Palo Alto Investors, an estimated $9.89M added.
  • The largest Iovance Biotherapeutics seller in Q3 2025 was Millennium Management, an estimated $11.6M sold.

Based on aggregated 13F filings for Q3 2025.